Patents by Inventor Bangliang LI

Bangliang LI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230357148
    Abstract: The invention relates to an indole derivative shown in general formula (I-1) and its use in preparing drugs for preventing and/or treating indications of S1P receptor related disorders. The indole derivative of the invention is replaced by R1, R2, R5, and R6 at different sites respectively, and the obtained modified indole derivative has excellent biological activity and is an ideal S1P receptor regulator with high efficiency. Compounds of general formula (I-1) can be used to treat and/or prevent Crohn's disease, ulcerative colitis, psoriasis, rheumatoid arthritis, multiple sclerosis, atopic dermatitis, eosinophilic esophagitis, alopecia areata, primary cholangitis, pyoderma gangrenosum, graft-versus-host disease, amyotrophic lateral sclerosis, systemic lupus erythematosus, type I diabetes arteriosclerosis, atherosclerosis, scleroderma, autoimmune hepatitis, acne, microbial infection, viral infection, and other autoimmune and inflammatory diseases.
    Type: Application
    Filed: July 2, 2021
    Publication date: November 9, 2023
    Inventors: Feng REN, Yubin LV, Hailong WANG, Yueying REN, Chunlin CHEN, Yangchun LUO, Jinna CAI, Bangliang LI
  • Publication number: 20230035182
    Abstract: An intelligent production line for motor pulley, include a processing mechanism; a feeding mechanism; a grasping mechanism; a detection mechanism, including a photographing device, a light source, a positioning block, and an image processing unit, the positioning block is used to place the pulley to be detected, the light source is used to illuminate the pulley to be detected, and the photographing device is arranged in the backlight direction of the light source, the image processing unit is used for acquiring the workpiece image of the pulley to be detected through the photographing device and detecting the workpiece parameters of the pulley to be detected through the workpiece image; a feedback mechanism, which communicates and connects the detection mechanism and the processing mechanism, and is used for acquiring the workpiece parameters and adjusting the processing parameters of the processing mechanism according to the parameters.
    Type: Application
    Filed: July 25, 2022
    Publication date: February 2, 2023
    Inventors: PEIKAI ZHANG, YE JIANG, BANGLIANG LI, HUANLE LIN, LUFEN ZENG, HEPENG SUN, JIANGBIN SU
  • Publication number: 20210077515
    Abstract: The invention discloses a composition containing ?-nicotinamide mononucleotide and Cordyceps sinensis. The ratio of ?-nicotinamide mononucleotide to Cordyceps sinensis can be 2-5:1. The composition has the effects of improving NAD+ level in vivo, repairing DNA, maintaining cell health, promoting NADP synthesis, and increasing immunity. The combination of ?-nicotinamide mononucleotide and Cordyceps sinensis can strengthen various effects, create synergistic effect, and thus the present composition is suitable for the majority of people.
    Type: Application
    Filed: November 26, 2020
    Publication date: March 18, 2021
    Inventors: Bangliang LI, Caihong XU
  • Patent number: 10822339
    Abstract: The present invention relates to a pyrrolopyrimidine five-membered azacyclic derivative as a novel JAK kinase inhibitor, and use thereof in a preparation of a pharmaceutical product for preventing and/or treating an indication related to a JAK kinase function. The pyrrolopyrimidine five-membered azacyclic derivative of the invention is an ideal JAK kinase inhibitor with a high potency, and can be used to treat or prevent diseases such as rheumatoid arthritis, polycythemia vera, psoriasis, primary thrombocytosis, myelofibrosis, and the like.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: November 3, 2020
    Assignees: HANGZHOU HUADONG MEDICINE GROUP BIOPHARMACEUTICAL CO. LTD
    Inventors: Jianming Yin, Yubin Lv, Bangliang Li
  • Patent number: 10640470
    Abstract: Disclosed are crystal forms K, E, F and G of the dimaleate of the compound as shown in formula I, and preparation methods and uses thereof. The crystal forms K, E, F and G have superior storage stability and solubility, so that they are more suitable for being used as the drug substance for drug product preparations.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: May 5, 2020
    Assignee: HANGZHOU HUADONG MEDICINE GROUP BIOPHARMACEUTICAL CO. LTD.
    Inventors: Yubin Lv, Jianming Yin, Xuehui Huang, Bangliang Li
  • Patent number: 10640512
    Abstract: Imidazopyrazinamine phenyl derivatives, pharmaceutically acceptable salts and hydrates thereof, or metabolites thereof formed by any form of metabolism, and uses thereof in the preparation of medicaments for preventing and/or treating indications/diseases associated with BTK functions are disclosed. The disclosed imidazopyrazinamine phenyl derivatives are ideal high-efficient BTK inhibitors for treating or preventing diseases such as rheumatoid arthritis, B cell lymphoma, leukemia, multiple myeloma, allergies, asthma, multiple sclerosis, type I diabetes and systemic lupus erythematosus.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: May 5, 2020
    Assignee: HANGZHOU SANYINTAI PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Jianming Yin, Yubin Lv, Bangliang Li
  • Publication number: 20190211023
    Abstract: Imidazopyrazinamine phenyl derivatives, pharmaceutically acceptable salts and hydrates thereof, or metabolites thereof formed by any form of metabolism, and uses thereof in the preparation of medicaments for preventing and/or treating indications/diseases associated with BTK functions are disclosed. The disclosed imidazopyrazinamine phenyl derivatives are ideal high-efficient BTK inhibitors for treating or preventing diseases such as rheumatoid arthritis, B cell lymphoma, leukemia, multiple myeloma, allergies, asthma, multiple sclerosis, type I diabetes and systemic lupus erythematosus.
    Type: Application
    Filed: June 29, 2017
    Publication date: July 11, 2019
    Applicant: HANGZHOU SANYINTAI PHARMACEUTICAL TECHNOLOGY CO.,LTD.
    Inventors: Jianming YIN, Yubin LV, Bangliang LI
  • Publication number: 20190040068
    Abstract: A pyrrolopyrimidine five-membered azacyclic derivative as a novel JAK kinase (Janus kinase) inhibitor, and use thereof in a preparation of a pharmaceutical product for preventing and/or treating an indication related to a JAK kinase function. The pyrrolopyrimidine five-membered azacyclic derivative is an ideal JAK kinase inhibitor with a high potency, and can be used to treat or prevent diseases such as rheumatoid arthritis, polycythemia vera, psoriasis, primary thrombocytosis, myelofibrosis, and the like.
    Type: Application
    Filed: January 25, 2017
    Publication date: February 7, 2019
    Inventors: Jianming YIN, Yubin LV, Bangliang LI
  • Publication number: 20180312472
    Abstract: Disclosed are crystal forms K, E, F and G of the dimaleate of the compound as shown in formula I, and preparation methods and uses thereof. The crystal forms K, E, F and G have superior storage stability and solubility, so that they are more suitable for being used as the drug substance for drug product preparations.
    Type: Application
    Filed: June 25, 2018
    Publication date: November 1, 2018
    Inventors: Yubin LV, Jianming YIN, Xuehui HUANG, Bangliang LI
  • Patent number: 10065931
    Abstract: Disclosed are crystal forms K, E, F and G of the dimaleate of the compound as shown in formula I, and preparation methods and uses thereof. The crystal forms K, E, F and G have superior storage stability and solubility, so that they are more suitable for being used as the drug substance for drug product preparations.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: September 4, 2018
    Assignee: HANGZHOU HUADONG MEDICINE GROUP BIOPHARMACEUTICAL CO. LTD.
    Inventors: Yubin Lv, Jianming Yin, Xuehui Huang, Bangliang Li
  • Publication number: 20180134668
    Abstract: Disclosed are crystal forms K, E, F and G of the dimaleate of the compound as shown in formula I, and preparation methods and uses thereof. The crystal forms K, E, F and G have superior storage stability and solubility, so that they are more suitable for being used as the drug substance for drug product preparations.
    Type: Application
    Filed: May 3, 2016
    Publication date: May 17, 2018
    Inventors: Yubin LV, Jianming YIN, Xuehui HUANG, Bangliang LI